title: ACR Appropriateness Criteria® role of adjuvant therapy in the management of early stage cervical cancer.
abstract: OBJECTIVE
  The use of adjuvant treatment(s) following initial hysterectomy and retroperitoneal nodal harvesting of patients with clinical stage I and II cervical carcinoma is (are) presently based on the pathological assessment of surgical specimens. This report sought to delineate further the clinical application of potential therapeutic interventions and associated follow-up investigations of this patient cohort.
  
  
  METHODS
  The American College of Radiology (ACR) Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every two years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journal and the application of a well-established consensus methodology (modified Delphi) to rate appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
  
  
  RESULTS
  From this process, 5 unique clinical variants were developed. These scenarios pertained to options of adjuvant radiation therapy and chemotherapy, methods of delivery of radiotherapy to optimize target volume coverage while simultaneously minimizing radiation exposure of adjacent healthy organs, and recommendations for patient follow-up care. Group members reached consensus of topic ratings in descending order of importance. A risk assessment breakdown was established to highlight the most likely indications for adjuvant treatment(s).
  
  
  CONCLUSIONS
  This assembly by the ACR of physicians involved in the management of patients with early stage cervical cancer was able to describe appropriateness criteria to aid other practitioners in selecting reasonable implementation of postoperative therapies and subsequent surveillance studies. These guidelines await further validation and refinement by both current and future prospectively randomized clinical studies regarding this patient population.
authors.affiliation: University of Miami, Miami, FL, USA. AWolfson@med.miami.edu
authors.forename: Aaron H
authors.initials: AH
authors.lastname: Wolfson
authors.forename: Mahesh A
authors.initials: MA
authors.lastname: Varia
authors.forename: David
authors.initials: D
authors.lastname: Moore
authors.forename: Gautam G
authors.initials: GG
authors.lastname: Rao
authors.forename: David K
authors.initials: DK
authors.lastname: Gaffney
authors.forename: Beth A
authors.initials: BA
authors.lastname: Erickson-Wittmann
authors.forename: Anuja
authors.initials: A
authors.lastname: Jhingran
authors.forename: Nina A
authors.initials: NA
authors.lastname: Mayr
authors.forename: Ajmel A
authors.initials: AA
authors.lastname: Puthawala
authors.forename: William
authors.initials: W
authors.lastname: Small
authors.forename: Catheryn M
authors.initials: CM
authors.lastname: Yashar
authors.forename: William
authors.initials: W
authors.lastname: Yuh
authors.forename: Higinia Rosa
authors.initials: HR
authors.lastname: Cardenes
mesh_terms: D017024:Chemotherapy, Adjuvant; D003697:Delphi Technique; D005260:Female; D006801:Humans; D007044:Hysterectomy; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D020266:Radiotherapy, Conformal; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000628:therapy